Agilent Acquires BIOVECTRA

Agilent Technologies Acquisition Overview

Learn more about Agilent’s acquisition with BIOVECTRA. 

Press Release

Agilent Completes Acquisition of BIOVECTRA

Press Release

Agilent Completes Acquisition of BIOVECTRA
Read Press Release

Frequently Asked Questions

Learn more about the acquisition

Frequently Asked Questions

The following frequently-asked-questions provide current and future customers of Agilent and BIOVECTRA with general information, new capabilities we can now offer, and how to learn more.
Read FAQs

Press Release

Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care

Press Release

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of […]
Read Press Release

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications